Proteios Technology

Executive Summary

Proteios Technology is a San Diego-based biotechnology company developing a novel, label-free cell isolation and processing platform for advanced cell and gene therapies. The technology enables automated, high-efficiency isolation of target cells using multiple markers without leaving antibodies or beads, addressing key manufacturing challenges in cell therapy. Originally founded in 2019 to commercialize a protein purification technology from the University of Washington, the company pivoted to focus on empowering cell therapy research and manufacturing. Its platform offers potential for reduced costs, improved purity, and scalability, positioning it as a critical enabler in the growing cell therapy market. While still in early stages with limited public financial or clinical data, Proteios' technology could differentiate from existing magnetic bead-based methods. The company's success will depend on securing partnerships with cell therapy developers, demonstrating platform reproducibility, and raising additional capital to advance commercialization. The upcoming catalyst of a Series A fundraising round is critical for scaling operations and initiating pilot programs with key industry partners.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026First Commercial Partnership with Cell Therapy Developer50% success
• Q2 2026Publication of Platform Validation Data in Peer-Reviewed Journal60% success